Amicus Therapeut Stock Price, News & Analysis

Amicus Therapeutics (Nasdaq: FOLD) reported strong Q2 2024 financial results with total revenue of $126.7 million, a 34% year-over-year increase. Galafold revenue grew by 17% to $110.8 million, and Pombiliti + Opfolda revenue rose 44% from Q1 2024 to $15.9 million. The company raised its 2024 revenue growth guidance to 26%-31% and Galafold growth guidance to 14%-18%. Non-GAAP operating expenses are now expected to be between $345 million to $360 million. For Q2 2024, Amicus achieved non-GAAP profitability with a net income of $18.5 million and a GAAP net loss of $15.7 million. Cash reserves stood at $260.1 million as of June 30, 2024. The company is on track to achieve its Pombiliti + Opfolda revenue target of $62 million to $67 million for 2024.

Amicus Therapeutics (Nasdaq: FOLD) has announced its upcoming second quarter 2024 financial results conference call and webcast, scheduled for August 8, 2024, at 8:30 a.m. ET. The event will cover financial results for the quarter ended June 30, 2024. Participants can access the call via phone by registering online to receive a dial-in number and personal PIN. A live audio webcast and presentation materials will be available through the Investors section of the Amicus Therapeutics website.

Amicus Therapeutics is a global biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The company emphasizes patient dedication and is committed to advancing a pipeline of first- or best-in-class treatments for rare diseases.

Amicus Therapeutics (Nasdaq: FOLD) announced that its management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL, on June 11, 2024, at 4:00 p.m. E.T.

The live audio webcast of the presentation will be accessible via the investors section of the Amicus Therapeutics website. Amicus Therapeutics is a biotechnology firm focused on developing medicines for rare diseases, committed to advancing a pipeline of innovative treatments.

Amicus Therapeutics (Nasdaq: FOLD) announced that its two-component therapy, Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), has won the 2024 Prix Galien U.K. Award for Best Pharmaceutical Product. This prestigious award celebrates outstanding advances in the discovery and development of innovative products that improve human health. Pombiliti + Opfolda is the first and only therapy for eligible adults with late-onset Pompe disease, a debilitating lysosomal disorder. The award underscores the dedication of Amicus Therapeutics and the broader Pompe community in addressing this rare disease. The Galien Foundation, responsible for these awards, is committed to fostering innovation in medical science.

Amicus Therapeutics reported a total revenue of $110.4M for 1Q 2024, showing a 28% increase year-over-year. They raised their full-year 2024 revenue growth guidance to 25%-30%. Galafold sales increased by 15%, with Pombiliti + Opfolda sales growing by 30%. Non-GAAP profitability is projected for 2024. The company aims to achieve double-digit Galafold revenue growth and launch Pombiliti + Opfolda successfully.

Amicus Therapeutics will participate in the Bank of America 2024 Health Care Conference in Las Vegas. The company aims to present its dedication to developing medicines for rare diseases. The event will feature a fireside chat with management on May 15, 2024, at 1:40 p.m. P.T.

Amicus Therapeutics (Nasdaq: FOLD) will announce its first-quarter 2024 financial results on May 9, 2024. A conference call and live webcast will be held to discuss the results. The company is a global biotechnology firm focused on developing medicines for rare diseases.